Literature DB >> 19022512

Cytotoxicity and immunostimulation: double attack on cancer cells with polymeric therapeutics.

Blanka Ríhová1, Lubomír Kovár, Marek Kovár, Ondrej Hovorka.   

Abstract

The successful treatment of cancer with conventional drugs is frequently complicated by the resistance of tumor cells to such a non-specific therapy. Over the last few years, immunotherapy has gained attention as a tumor-specific approach. Recent findings demonstrated that some conventional cytostatics stimulate local anticancer responses. New anticancer drugs, including their polymeric derivatives, are currently being developed with the aim of destroying tumors more effectively and more specifically. Among these, the water-soluble conjugates of doxorubicin with N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer carrier have emerged as efficient therapeutics because they are able to not only directly destroy cancer cells but also elicit systemic tumor-specific anticancer responses. Here, we discuss new insights into their mechanisms of immune surveillance, which could suggest novel approaches to cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19022512     DOI: 10.1016/j.tibtech.2008.10.006

Source DB:  PubMed          Journal:  Trends Biotechnol        ISSN: 0167-7799            Impact factor:   19.536


  12 in total

1.  The Light at the End of the Tunnel-Second Generation HPMA Conjugates for Cancer Treatment.

Authors:  Jiyuan Yang; Jindřich Kopeček
Journal:  Curr Opin Colloid Interface Sci       Date:  2017-07-28       Impact factor: 6.448

2.  Inhibition of Immunosuppressive Tumors by Polymer-Assisted Inductions of Immunogenic Cell Death and Multivalent PD-L1 Crosslinking.

Authors:  Lian Li; Yachao Li; Chieh-Hsiang Yang; D Christopher Radford; Jiawei Wang; Margit Janát-Amsbury; Jindřich Kopeček; Jiyuan Yang
Journal:  Adv Funct Mater       Date:  2020-02-03       Impact factor: 18.808

Review 3.  Design of smart HPMA copolymer-based nanomedicines.

Authors:  Jiyuan Yang; Jindřich Kopeček
Journal:  J Control Release       Date:  2015-10-03       Impact factor: 9.776

4.  Doxorubicin attached to HPMA copolymer via amide bond modifies the glycosylation pattern of EL4 cells.

Authors:  Lubomir Kovar; Tomas Etrych; Martina Kabesova; Vladimir Subr; David Vetvicka; Ondrej Hovorka; Jiri Strohalm; Jan Sklenar; Petr Chytil; Karel Ulbrich; Blanka Rihova
Journal:  Tumour Biol       Date:  2010-02-24

Review 5.  Prospective of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell apoptosis.

Authors:  Jayshree Mishra; Joseph Drummond; Sohel H Quazi; Satya Sridhar Karanki; J J Shaw; Ben Chen; Narendra Kumar
Journal:  Crit Rev Oncol Hematol       Date:  2012-10-23       Impact factor: 6.312

6.  Preclinical evaluation of linear HPMA-doxorubicin conjugates with pH-sensitive drug release: efficacy, safety, and immunomodulating activity in murine model.

Authors:  Milada Sirova; Tomas Mrkvan; Tomas Etrych; Petr Chytil; Pavel Rossmann; Marketa Ibrahimova; Lubomir Kovar; Karel Ulbrich; Blanka Rihova
Journal:  Pharm Res       Date:  2009-11-06       Impact factor: 4.200

Review 7.  Polymer-drug conjugates: origins, progress to date and future directions.

Authors:  Jindřich Kopeček
Journal:  Adv Drug Deliv Rev       Date:  2012-11-02       Impact factor: 15.470

8.  HPMA-based star polymer biomaterials with tuneable structure and biodegradability tailored for advanced drug delivery to solid tumours.

Authors:  Libor Kostka; Lenka Kotrchová; Vladimír Šubr; Alena Libánská; Carolina A Ferreira; Iva Malátová; Hye Jin Lee; Todd E Barnhart; Jonathan W Engle; Weibo Cai; Milada Šírová; Tomáš Etrych
Journal:  Biomaterials       Date:  2019-12-26       Impact factor: 12.479

9.  HPMA copolymers: origins, early developments, present, and future.

Authors:  Jindrich Kopecek; Pavla Kopecková
Journal:  Adv Drug Deliv Rev       Date:  2009-11-14       Impact factor: 15.470

10.  Cathepsin B-responsive and gadolinium-labeled branched glycopolymer-PTX conjugate-derived nanotheranostics for cancer treatment.

Authors:  Hao Cai; Yufan Xiang; Yujun Zeng; Zhiqian Li; Xiuli Zheng; Qiang Luo; Hongyan Zhu; Qiyong Gong; Zhongwei Gu; Yanhui Liu; Hu Zhang; Kui Luo
Journal:  Acta Pharm Sin B       Date:  2020-08-14       Impact factor: 11.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.